CN104606665A - Therapeutic formula for bone metastasis pain based on bone marrow puncture - Google Patents
Therapeutic formula for bone metastasis pain based on bone marrow puncture Download PDFInfo
- Publication number
- CN104606665A CN104606665A CN201510074668.5A CN201510074668A CN104606665A CN 104606665 A CN104606665 A CN 104606665A CN 201510074668 A CN201510074668 A CN 201510074668A CN 104606665 A CN104606665 A CN 104606665A
- Authority
- CN
- China
- Prior art keywords
- bone
- pain
- formula
- treatment
- bone marrow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a therapeutic formula for bone metastasis pain based on bone marrow puncture. The formula is characterized by consisting of 1 to the power of 12PV of a recombinant human P53 injection, 50u of rhGM-CSF and 2ml of physiological saline; the control group of the method is anti-tumor combined zoledronic acid treatment. The therapeutic formula for bone metastasis pain based on bone marrow puncture disclosed by the invention can be used for controlling the bone metastasis pain in a mode of administration through bone marrow puncture; the formula can be used for significantly relieving or curing the bone metastasis pain within 24, and the pain degrees of two groups are reduced; on 50 cases, the formula is completely effective, and the effective rate is 96%; on 19 cases of the control group, the effective rate is 63.33%; and the comparative differences of the two groups have statistical significance.
Description
Technical field
The present invention relates to a kind for the treatment of formula for Bone tumour pain based on bone marrow puncture.
Background technology
Bone tumour is one of pulmonary carcinoma major complications. cardinal symptom comprises degradation under pain, pathologisch Bruch, the spinal compression of vertebral body transfer, hypercalcemia and general status.Pulmonary carcinoma occurs that Bone tumour prognosis is poor.Thus subtract disease treatment extremely important, the quality of life of patient can be significantly improved.The Pathophysiology of Bone tumour and the metabolism of clinical symptoms normal bone relate to the balance between bone resorption and new bone formation.Tumor cell can not maintain this balance, and bone contains a large amount of propagation regulatory factors, is the optimum environment of tumor cell [1].Many endocrine regulation factors, all participate in bone remodeling process normal cell as tumor necrosis factor, IL 1, IL 1, OAF and prostaglandin and tumor cell all can secrete these factors, to stimulate osteoclast activity.In addition, tumor agent can also activate bone matrix release multiplicaiton factor, promotes tumor proliferative.Bone tumour be primary tumo(u)r by blood dissemination to euangiotic skeletal sites continued growth, main manifestations be diffuse periostitis, sclerotin interrupt or osteolytic tumor, three can occur simultaneously.The most common metastasis site is pelvis, rib, vertebral body and long bone, particularly femur.Tip long bone is seldom involved [2].Bone metastases of lung cancer is bone-solveddestructed lesion normally, when the strength reduction of bone, may cause pathologisch Bruch.The position of most commonly encountered diseases rationality fracture is rib and vertebral body. but another common site vertebral body transfer becoming pathologisch Bruch due to femur load-bearing reason causes differential expansion or subsides and cause spinal compression.If often show as backache. non-Timeliness coverage. neurological sequelae [3-4] that is serious and irreversibility can be caused.Although research is comparatively clear on pathology, the treatment for bone metastases of lung cancer still faces the challenge for a comparatively long period of time.
Patients with lung cancer generation Bone tumour, clinically generally belongs to late period, and only 3 months .5 survival rates are lower than 2% with life span in the pulmonary carcinoma of Bone tumour report, and prompting Bone tumour is one of factor of Lung Cancer in Old-aged Patients prognosis mala.Late tumor pain is a world-famous puzzle, and especially Whole Body Bone Scanning shifts the pain caused, and allows a lot of clinician have no way out, and a lot of patient is also difficult to effective pain relieving by chemicotherapy, malicious anaesthetic thing Three-step analgesia.Therefore the deep further research carrying out associating Chinese medicine Bone tumour, just seems particularly important.
Therefore, prior art needs to be improved.
Summary of the invention
The object of the invention is to provide a kind for the treatment of formula for Bone tumour pain based on bone marrow puncture for overcoming the deficiencies in the prior art, reach the control to Bone tumour pain by the approach of bone marrow aspiration administration, within 24 hours, obviously alleviate or cure Bone tumour pain.
For solving the problems of the technologies described above, a kind for the treatment of formula for Bone tumour pain based on bone marrow puncture that the embodiment of the present invention provides, adopts following technical scheme:
Based on the treatment formula for Bone tumour pain of bone marrow puncture, it is characterized in that, described formula is composed as follows: recombined human P53 injection 1X10
12pV, rhGM-CSF 50u, normal saline 2ml.
Particularly, described method matched group is antineoplastic combination Zoledronic Acid in Treatment.
A kind for the treatment of formula for Bone tumour pain based on bone marrow puncture provided by the invention, the control to Bone tumour pain is reached by the approach of bone marrow aspiration administration, within 24 hours, obviously alleviate or cure Bone tumour pain, two groups of pain degrees all have decline, and treatment 50 example is fully effective, and effective percentage is 96%, matched group is 19 examples, effective percentage is 63.33%, and treatment Bone tumour pain effective percentage reaches 96%, and two groups of comparing differences have statistical significance.
Detailed description of the invention
A kind for the treatment of formula for Bone tumour pain based on bone marrow puncture that the embodiment of the present invention provides, it is characterized in that, described formula is composed as follows: recombined human P53 injection 1X10
12pV, rhGM-CSF 50u, normal saline 2ml.
Particularly, described method matched group is antineoplastic combination Zoledronic Acid in Treatment.
Experiment case study:
Choose between year May in July, 2011 to 2012, to our hospital and be diagnosed as bone metastases of lung cancer patient, amount to 60 examples, man 47 example, female 13 example, 35 years old-77 years old age, the median age 51 years old, wherein scale cancer 23 example, adenocarcinoma 29, small cell carcinoma 8 example; Treatment group: scale cancer 10 example, adenocarcinoma 15 example, minicell 5 example, mild pain 13 example, moderate pain 12 example, severe pain 5 example; Matched group: scale cancer 13 example, adenocarcinoma 14 example, minicell 3 example, mild pain 17 example, moderate pain 11 example, severe pain 2 example.According to the state of an illness, patient can accept the treatments such as radiotherapy, chemotherapy, oral analgesic, and through statistical procedures, two groups of patients all have comparability in age, sex, pain degree, histological type etc.
1.2 inclusive criteria
All patients are all deficiency of both QI and YIN disease type through Chinese medical discrimination, and pathology or cytology are diagnosed as pulmonary carcinoma; And be diagnosed as Bone tumour through CT, MRI, ECT or PET/CT inspection, and with the slight above pain of corresponding site; Enter to organize not accept by the previous moon Diphosphonate treatment; Estimate life cycle and be greater than 3 months; KPS scoring >=40 points; Without liver, kidney, impaired heart function person; Interdependence is good.
2 methods
2.1 Therapeutic Method
Treatment group: adopt bone marrow puncture to carry out administration.Matched group: antineoplastic combination Zoledronic Acid in Treatment.
2.2 efficacy evaluation
Pain degree classification: pain degree adopts NRS point system, 0 point: do not have pain; 1 ~ 3 point: mild pain, can stand, can orthobiosis, sleep substantially interference-free: 4 ~ 6 points: moderate pain, the pain continued, sleep is interfered, and need use analgesic: 7 ~ 9 points: severe pain, strong lasting, sleep is seriously interfered, and need use strong analgesics; 10 points: the pain that can occur.
Mobility: 0 grade for activity freely, unaffected; I level is that activity is slightly limited, and life still can be taken care of oneself; II level is that activity is obviously limited, needs people to help; III level is completely limited for living, and is unable to leave the bed.
Quality of life: by KPS standards of grading.
2.3 criterion of therapeutical effect
Pain relief grading: complete incidence graph (CR): after treatment, NRS is for dividing 0; Partial rcsponse (PR): after radiotherapy, the decline of NRS score value is more than or equal to 2 points; Nothing alleviates (NR): the decline for the treatment of rear NRS score value is less than or equal to 1 point or comparatively front and raises.Take CR+PR as effective percentage.
Mobility: effective: mobility improves II level or more; Effective: mobility improves I level; Invalid: mobility does not improve or weakens.
Quality of life: KPS marks, comparatively increase before treatment after treatment 20 points and above be significantly improvement; Increase by 10 and be divided into improvement; Stable without increasing to; Reduce 10 points and following for decline.
2.4 side effect evaluations
Observe patient with or without performances such as heating, Nausea and vomiting.Check 1 routine blood test weekly, every 4 weeks check 1 Liver and kidney function and electrocardiogram.The grade scale of cancer therapy drug toxicity 0 ~ IV degree totally 5 ranks of recommending by WHO, evaluates the adverse events occurred in research, and analyzes its dependency with treatment.
2.5 statistical analysis
All data all carry out statistical procedures through SPSS 17.0 statistical software, the data obtained meets normal distribution person, adopt t inspection and x
2statistical analysis is carried out in inspection; Data do not meet normal distribution person, adopts rank test to carry out statistical analysis.P < 0.05 has statistical significance.
3 results:
3.1 bone pain palliations: two groups of pain degrees all have decline, treatment group is effectively 27 examples, and effective percentage is 90%, and matched group is 19 examples, and effective percentage is that 63.33%, two groups of comparing differences have statistical significance (P=0.015).In table 1.
After table 1 liang group treatment, pain symptom improves situation
3.2 mobilities: treatment group: effective 13 examples, effective 11 examples, invalid 6 examples, effective percentage is 80%; Matched group: effective 9 examples, effective 7 examples, invalid 14 examples, effective percentage is 53.33%; Two groups of comparing differences have statistical significance (P=0.028).In table 2.
After table 2 liang group treatment, mobility improves situation
3.3 quality of lifes: treatment group: significantly improve 7 examples, improve 18 examples, without increasing or reduce 5 examples, effective percentage is 83.33%; Matched group: significantly improve 5 examples, improves 13 examples, and without increasing or reduce 12 examples, effective percentage is 60%; Two groups of comparing differences have statistical significance (P=0.045).In table 3.
After table 3 liang group treatment, quality of life improves situation
Table 4 treat before and after traditional Chinese medical science cardinal symptom integration comparison (; ± s)
Very significant statistical significance (t checks, P < 0.01) is all had in the symptom improvement of comparatively weak in lusterless complexion, weak breath before treatment after treatment, easy catching a cold, feverish sensation in the palms and soles, afternoon low grade fever, lumbago, dry mouth and throat etc.; Result has statistical significance.
3.2 untoward reaction
Two groups of adverse reaction rates compare, and two groups of untoward reaction mostly are light moderate, can alleviate through anti symptom treatment.Untoward reaction main manifestations is Nausea and vomiting etc., and adverse reaction rate compares, difference there are no significant meaning.
A kind for the treatment of formula for Bone tumour pain based on bone marrow puncture provided by the invention, the control to Bone tumour pain is reached by the approach of bone marrow aspiration administration, within 24 hours, obviously alleviate or cure Bone tumour pain, two groups of pain degrees all have decline, treatment 30 example is fully effective, and effective percentage is 96%, and matched group is 19 examples, effective percentage is that 63.33%, two groups of comparing differences have statistical significance.
The above; be only the specific embodiment of the present invention, but protection scope of the present invention is not limited thereto, is anyly familiar with those skilled in the art in the technical scope that the present invention discloses; change can be expected easily or replace, all should be encompassed within protection scope of the present invention.Therefore, protection scope of the present invention should described be as the criterion with the protection domain of claim.
Claims (2)
1. based on the treatment formula for Bone tumour pain of bone marrow puncture, it is characterized in that, described formula is composed as follows: recombined human P53 injection 1X10
12pV, rhGM-CSF 50u, normal saline 2ml.
2. based on the treatment formula for Bone tumour pain of bone marrow puncture, it is characterized in that, described method matched group is antineoplastic combination Zoledronic Acid in Treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510074668.5A CN104606665A (en) | 2015-02-13 | 2015-02-13 | Therapeutic formula for bone metastasis pain based on bone marrow puncture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510074668.5A CN104606665A (en) | 2015-02-13 | 2015-02-13 | Therapeutic formula for bone metastasis pain based on bone marrow puncture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104606665A true CN104606665A (en) | 2015-05-13 |
Family
ID=53141487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510074668.5A Pending CN104606665A (en) | 2015-02-13 | 2015-02-13 | Therapeutic formula for bone metastasis pain based on bone marrow puncture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104606665A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104066443A (en) * | 2011-11-09 | 2014-09-24 | 沃纳·卢比茨 | Vaccine for tumor immunotherapy |
-
2015
- 2015-02-13 CN CN201510074668.5A patent/CN104606665A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104066443A (en) * | 2011-11-09 | 2014-09-24 | 沃纳·卢比茨 | Vaccine for tumor immunotherapy |
Non-Patent Citations (2)
| Title |
|---|
| 林健泽: "重组人P53腺病毒经皮穿刺瘤内注射治疗脊柱转移瘤的临床研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 欧阳学农 等: "重组人粒细胞-巨噬细胞集落刺激因子新用途", 《解放军药学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davies et al. | Palliative care | |
| Kumar et al. | Comparison of conventional infrainguinal versus modified proximal suprainguinal approach of Fascia Iliaca Compartment Block for postoperative analgesia in Total Hip Arthroplasty. A prospective randomized study | |
| Liu et al. | Spontaneous versus mechanical ventilation during video-assisted thoracoscopic surgery for spontaneous pneumothorax: a randomized trial | |
| WO2015024420A1 (en) | Local anesthesia pain-relieving time-delay agent | |
| Azreen et al. | Langerhans cell histiocytosis of maxillary sinus | |
| Su et al. | Analgesic efficacy of bilateral superficial and deep cervical plexus block in patients with secondary hyperparathyroidism due to chronic renal failure | |
| Farley‐Hills et al. | Tumour lysis syndrome during anaesthesia | |
| CN104606665A (en) | Therapeutic formula for bone metastasis pain based on bone marrow puncture | |
| CN104383633A (en) | Bone marrow puncture-based treatment method for bone metastasis pain | |
| Gupta et al. | Transverse Abdominal Plane Neurostimulation for Chronic Abdominal Pain: A Novel | |
| Apalla et al. | Possible zoledronic acid‐induced dermatomyositis | |
| Zhao et al. | Randomized efficacy trial of conventional, TCM Herb, and TEAS on bone marrow suppression in patients with small cell lung cancer after initial chemotherapy | |
| Kang et al. | Sequential bipolar radiofrequency lumbar sympathectomy in Raynaud's disease-A case report | |
| Gofeld et al. | Bilateral pain relief after unilateral thoracic percutaneous sympathectomy | |
| Ai | Effects of dexmedetomidine combined with dezocine on T lymphocytes, NK cells and cognitive function in elderly patients with gastrointestinal cancer after radical surgery | |
| Proud | The use of oral transmucosal fentanyl citrate during high-dose-rate gynecologic brachytherapy. | |
| Kwon et al. | A Retrospective Clinical Analysis of 1,485 Patients Who Visited the Emergency Room of Korean Medical Hospital with Musculoskeletal Disorders | |
| Oliveira et al. | Invasive treatment to control neuropathic pain | |
| CN106485092A (en) | Application of the patient-controlled intrathecal analgesic techniques combining information management in Pain Treatment | |
| Siddiqui | Caudal blockade in children | |
| Lingfei et al. | TACE with Ar-He cryosurgery combined minimal invasive technique for the treatment of primary NSCLC in 139 cases | |
| Yang et al. | Clinical observation on warm needling moxibustion plus acupoint sticking therapy for cervical radiculopathy | |
| Greengrass et al. | Paravertebral blockade for inguinal herniorrhaphy novice performance of anatomic versus nerve stimulator-guided techniques | |
| Zhao et al. | Clinical observation on comprehensive treatment on cutaneous region for low back pain | |
| CN105078991A (en) | Medicine composition for preventing and treating nausea and emesis after TACE operation as well as application thereof and package |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150513 |